Favrille Announces Receipt of Nasdaq Letters
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the developmentand commercialization of targeted immunotherapies for the treatment of cancerand other diseases of the immune system.
Statements in this press release that are not strictly historical innature constitute "forward-looking statements." Such statements include, butare not limited to, references to Favrille's product candidates, proprietarytechnologies and research and clinical development programs. Such forward-looking statements involve known and unknown risks, uncertainties and otherfactors that may cause Favrille's actual results to be materially differentfrom historical results or from any results expressed or implied by suchforward-looking statements. These factors include, but are not limited to,risks and uncertainties related to Favrille's listing status and potentialdelisting of Favrille's common stock from The Nasdaq Global Market, Favrille'sability to continue its operations, conserve cash or recognize value on ourassets and additional risks discussed in Favrille's filings with theSecurities and Exchange Commission. All forward-looking statements arequalified in their entirety by this cautionary statement. Favrille isproviding this information as of the date of this release and, except asrequired by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information,future events or otherwise.
SOURCE Favrille, Inc.
You May Also Like